studies

squamous cell - mNSCLC - L1, anti-PD-(L)1 vs. Standard of Care (SoC), meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-407, 2018 0.64 [0.49; 0.84] 0.64[0.49; 0.84]KEYNOTE-407, 201810%559NAnot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-407, 2018 0.56 [0.45; 0.70] 0.56[0.45; 0.70]KEYNOTE-407, 201810%559NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-407, 2018 2.20 [1.57; 3.09] 2.20[1.57; 3.09]KEYNOTE-407, 201810%559NAnot evaluable AE (any grade)detailed resultsKEYNOTE-407, 2018 1.20 [0.36; 3.96] 1.20[0.36; 3.96]KEYNOTE-407, 201810%558NAnot evaluable AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.99 [0.70; 1.39] 0.99[0.70; 1.39]KEYNOTE-407, 201810%558NAnot evaluable AE leading to death (grade 5)detailed resultsKEYNOTE-407, 2018 1.31 [0.69; 2.49] 1.31[0.69; 2.49]KEYNOTE-407, 201810%558NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsKEYNOTE-407, 2018 2.28 [1.45; 3.61] 2.28[1.45; 3.61]KEYNOTE-407, 201810%558NAnot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.09 [1.28; 3.39] 2.09[1.28; 3.39]KEYNOTE-407, 201810%558NAnot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-407, 2018 1.70 [0.61; 4.75] 1.70[0.61; 4.75]KEYNOTE-407, 201810%558NAnot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 10.24 [0.56; 188.30] 10.24[0.56; 188.30]KEYNOTE-407, 201810%558NAnot evaluable Alopecia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.33 [0.03; 3.22] 0.33[0.03; 3.22]KEYNOTE-407, 201810%558NAnot evaluable Anaemia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.72 [0.46; 1.11] 0.72[0.46; 1.11]KEYNOTE-407, 201810%558NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.03 [0.37; 11.17] 2.03[0.37; 11.17]KEYNOTE-407, 201810%558NAnot evaluable Asthenia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.60 [0.21; 1.66] 0.60[0.21; 1.66]KEYNOTE-407, 201810%558NAnot evaluable Colitis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.04 [0.50; 8.23] 2.04[0.50; 8.23]KEYNOTE-407, 201810%558NAnot evaluable Constipation AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.67 [0.11; 4.04] 0.67[0.11; 4.04]KEYNOTE-407, 201810%558NAnot evaluable Cough AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.67 [0.11; 4.04] 0.67[0.11; 4.04]KEYNOTE-407, 201810%558NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.21 [0.37; 4.02] 1.21[0.37; 4.02]KEYNOTE-407, 201810%558NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.88 [0.69; 5.16] 1.88[0.69; 5.16]KEYNOTE-407, 201810%558NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 3.04 [0.31; 29.44] 3.04[0.31; 29.44]KEYNOTE-407, 201810%558NAnot evaluable Epistaxis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.01 [0.02; 50.94] 1.01[0.02; 50.94]KEYNOTE-407, 201810%558NAnot evaluable Fatigue AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.82 [0.33; 2.01] 0.82[0.33; 2.01]KEYNOTE-407, 201810%558NAnot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.02 [0.07; 60.40] 2.02[0.07; 60.40]KEYNOTE-407, 201810%558NAnot evaluable Hypophysitis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 4.05 [0.18; 90.23] 4.05[0.18; 90.23]KEYNOTE-407, 201810%558NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.02 [0.07; 60.40] 2.02[0.07; 60.40]KEYNOTE-407, 201810%558NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 4.07 [0.45; 36.67] 4.07[0.45; 36.67]KEYNOTE-407, 201810%558NAnot evaluable Myalgia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.02 [0.18; 22.43] 2.02[0.18; 22.43]KEYNOTE-407, 201810%558NAnot evaluable Nausea AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.75 [0.17; 3.39] 0.75[0.17; 3.39]KEYNOTE-407, 201810%558NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.90 [0.61; 1.32] 0.90[0.61; 1.32]KEYNOTE-407, 201810%558NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.52 [0.25; 9.15] 1.52[0.25; 9.15]KEYNOTE-407, 201810%558NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 3.07 [0.61; 15.32] 3.07[0.61; 15.32]KEYNOTE-407, 201810%558NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.01 [0.14; 7.20] 1.01[0.14; 7.20]KEYNOTE-407, 201810%558NAnot evaluable Severe skin reactions AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 3.04 [0.31; 29.44] 3.04[0.31; 29.44]KEYNOTE-407, 201810%558NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 1.07 [0.55; 2.08] 1.07[0.55; 2.08]KEYNOTE-407, 201810%558NAnot evaluable Thyroiditis AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 2.02 [0.07; 60.40] 2.02[0.07; 60.40]KEYNOTE-407, 201810%558NAnot evaluable Vomiting AE (grade 3-4)detailed resultsKEYNOTE-407, 2018 0.16 [0.02; 1.38] 0.16[0.02; 1.38]KEYNOTE-407, 201810%558NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-05-29 18:33 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 308,164,166,220 - treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons